

SWISS BIOTECH DAY 2025





Swiss Biotech Day 2025

Media conference

May 5, 2025, Congress Center Basel, Room Rio



Swiss Biotech Report 2025

Frederik Schmachtenberg, Michael Altorfer

May 5, 2025

Steering Committee Swiss Biotech Report 2025



Michael Altorfer



Frederik Schmachtenberg



Florian Fisch



Jan Lucht



Hans-Peter Meyer



Christian Moser Nikles



Jörg Schläpfer



Laura Suter-Dick



Sirpa Tsimal



Continuing resilience - commitment to international alliances

- Total revenues remain strong at CHF 7.2 billion
- Record CHF 833 million raised by privately funded companies drives 22% overall capital investment rise to CHF 2.5 billion
- Alentis Therapeutics (CHF 163 million) and SixPeaks Bio (CHF 102 million) lead the way in private rounds
- Despite market headwinds, some public companies report notable successes, e.g., Basilea and Santhera
- Significant M&A and licensing activity - Lonza, Numab, Idorsia, Moonlake, BioVersys, Haya and AC Immune
- Product approvals by FDA, EMA and Swissmedic increase, including, e.g., Idorsia's Aprocitentan and Basilea's Zevtera
- R&D investment continues to grow, reaching CHF 2.6 billion
- Increased demand from CDMO and private biotech R&D companies drives further employment growth of around 8%
- Swiss Biotech Day gains recognition as a premier global biotechnology conference with around 3'000 life sciences professionals






The year in figures



The data in the presented tables is based on information that was available up until March 31, 2025. At this time, some of the companies had not yet disclosed their financial figures for 2024. Therefore, some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e., Q3 or Q4 2024).

Capital investments in Swiss biotech companies 2015-2024

Private and public Swiss biotech companies



Source: Annual reports, website information, EY, Swiss Biotech Association

Swiss biotech companies raised a total of CHF 2.5 bn in 2024

Largest public and private financing rounds

2024 public financing rounds

PUBLIC COMPANIES	CHF MILLION
Lonza	1'125
CRISPR Therapeutics	247
ADC Therapeutics	96
Santhera Pharmaceuticals	69
Oculis	54
Total	1'590


2024 private financing rounds

PRIVATE COMPANIES	CHF MILLION
Alentis Therapeutics	163
SixPeaks	102
Asceneuron	90
iOnctura	76
Neurosterix	57
Total	488

Source: Annual reports, website information, EY, Swiss Biotech Association

Biotech financing categories in Switzerland 2015-2024

HISTORY OF FINANCING CATEGORIES IN SWITZERLAND



Source: Annual reports, website information, EY, Swiss Biotech Association


Public and private Swiss regional financing 2022-2024



Source: Annual reports, website information, EY, Swiss Biotech Association

Revenues, R&D expenses, profit/loss, liquidity 2022-2024

Total Swiss biotech companies




Source: Annual reports, website information, EY, SBA

Note: The 2024 data in above tables is based on information that was available up until March 31, 2025. At this time, some of the companies had not yet disclosed their financial figures for 2024. Therefore, some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e. Q3 or Q4 2024).

Revenues, R&D expenses, profit/loss, liquidity 2022-2024

Public Swiss biotech companies




Source: Annual reports, website information, EY, SBA

Note: The 2024 data in above tables is based on information that was available up until March 31, 2025. At this time, some of the companies had not yet disclosed their financial figures for 2024. Therefore, some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e. Q3 or Q4 2024).


Revenues, R&D expenses, profit/loss, liquidity 2022-2024

Private Swiss biotech companies




Source: Swiss Biotech Association, EY (incl. estimates and extrapolations based on prior year figures)

Number of biotech companies in Switzerland 2015-2024



Source: Annual reports, website information, EY, Swiss Biotech Association


Employees in Swiss R&D biotech companies 2022-2024



Source: Annual reports, website information, EY, Swiss Biotech Association

Immunological exports rise to CHF 52 billion

Therapeutic proteins, CGTs, and vaccines now represent 18.5% of Swiss exports



The life sciences sector has been the strongest contributor to Swiss exports every year since 2013



The Swiss Biotech Report 2025

The power of international alliances



The Swiss biotech industry

- Shows a small country can achieve significant global impact through collaboration
- Multiple Swiss ecosystem players - universities, hospitals, industry, associations and regulatory bodies - drive innovation and collaborations
- Benefits from a multinational talent pool that is collaborative by nature
- Develops most of its patents together with international partners
- Stays top of Global Innovation Index through international collaborations
- Comprises companies that collaborate internationally from inception
- Forms regulatory alliances to improve global access for innovative products
- Swiss Biotech Day's 'Global Village' confirms Switzerland offers a natural meeting place for the global biotech community

Strong private sector support underpins resilience

>95% of companies are privately funded



Alentis raised
CHF 163 million



SixPeaks Bio secured
CHF 102 million



Haya entered a
USD 1 billion discovery
collaboration with Lilly
for obesity drugs



Numab sells its
subsidiary Yellow Jersey
Therapeutics for USD
1.2 billion to J&J

Why the power of international alliances?

Because science knows no boundaries



“Conserving biodiversity is not only one of the greatest challenges facing humankind today - it is also a challenge that can only be tackled collectively. International alliances play a crucial role in ensuring that life in all its diversity continues to thrive on Earth.”


Severin Dressen
Director Zoo Zurich



A few examples of Swiss
biotech international
collaborations

Fostering research collaboration


The Eureka/Globalstars international grant network



“By fostering a culture of innovation and shared international knowledge, Swiss players consistently push the boundaries of what alliances can achieve.”

Encouraging sustainable innovation

Scienceindustries, the Swiss Biotech Association, SATW collaborate with the European Biosolutions Coalition



The potential of biosolutions is so enormous that it is hard to grasp. At the same time, to reap the rewards of available solutions, authorities, companies, and researchers must work together more closely; to make the transition happen, to clear judicial obstacles, and to apply novel solutions at a scale and volume that matters. This is the only way to translate biosolutions into significant reductions of greenhouse gas emissions, green jobs, and sustainable growth.

Harmonizing and accelerating the regulatory approval process

Swissmedic and the Access Consortium




The Access Consortium, formed by therapeutic products agencies from Australia, Canada, Singapore, Switzerland, and the UK, covers around 150 million people and aims to accelerate uptake of the latest therapies


Broadening research horizons

Swiss papers lead in international scientific collaboration and patent citations

Two thirds of Swiss papers result from collaborations with international partners



4 out of 5 biotech patents filed in Switzerland stem from international collaborations



The reputation of Swiss research institutes means that they are welcomed as partners in prestigious international networks.

Bringing people together


biotechnet inspires projects and meetings

Dr. Christina Zivko
Established the Center for
Extracellular Vesicle Research



Prof. Dr. Markus Seeger
Organizer of the Indo-Swiss
AMR Innovation Dialogue

With multinational backgrounds and study experiences, biotechnet experts push technological frontiers through their leadership of international projects and events



“In 2024 Swiss exports of chemicals and pharmaceuticals rose by CHF 13.6 billion (+10%) to a new record of CHF 149 billion, accounting for 52% of all exports. Immunologicals alone accounted for 18.5% of total exports from Switzerland.”

Jan Lucht
scienceindustries

“Swissmedic works closely with other regulatory authorities and is actively expanding partnerships to harmonize the authorization process for safe, effective and high-quality therapeutic products. This benefits both patients and companies.

Jörg Schläpfer
Swissmedic

“In an era when isolationist policies and “me first” approaches have gained traction, Switzerland’s collaborative model offers a compelling counterproposal. By fostering a culture of innovation and shared international knowledge, Swiss players consistently push the boundaries of what alliances can achieve.”

Michael Altorfer
Swiss Biotech Association

““Overall capital investments in the Swiss biotech industry were CHF 2.5 billion in 2024, an increase of 22% compared to the previous year. Private companies performed particularly well, with new record levels of financing and R&D expenses.”

Frederik Schmachtenberg
EY



“Science only functions if it is based on openness and cooperation, with researchers working and competing at a global level. SNSF grants fostering international exchange total around CHF 70 million/year.”

Florian Fisch

Swiss National Science
Foundation

“Biotechnology papers from Swiss institutions receive the highest average number of citations, both from scholars and in patents.”

Christian Moser Nikles
Swiss Federal Institute of
Intellectual Property

“Switzerland has an obligation to develop sustainable technological solutions for a less privileged global society, but this can only be achieved through international alliances and cooperation. Industrial biotechnology, driven by sustainability, is the next potential economic sector.”

Benoît Dubuis
SATW

“The secret to Swiss success lies in our ability to combine an industrious, bottom-up approach with an increasingly open mindset and the participation of top international talent in the knowledge economy.”

Laura Suter-Dick
Biotechnet

Global Village is our commitment to international collaboration



Internationally connected and interested in building bilateral relations



SWISS BIOTECH SUCCESS STORIES

Sponsors:



Supported by:

**WISSENSCHAFT.
BEWEGEN**
GEBERT RUF STIFTUNG | Basel-Stadt | TS Kommunikation

Organized by:





SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievement

- The Swiss Biotech Association annually awards individuals or organizations for outstanding contributions to the biotech industry
- Dedicated to scientists, pioneers, entrepreneurs, innovators and supporters who led the way, opened the horizon and prepared the ground for lasting achievements
- Swiss Biotech Success Stories accentuate past industry highlights and act as motivator for future achievements

Success Stories Award winners 2025



Dr. Dr. h.c. Henri B. Meier

Entrepreneurial leader,
venture capitalist,
and founder of the Swiss
Future Fund




Dr. Pascale Vonmont

CEO of Gebert Rüt
Stiftung, Switzerland's
largest private science
and innovation foundation
for over 25 years

**SWISS BIOTECH
SUCCESS STORIES**

Celebrating and honoring
major achievements

Swiss Biotech Report 2025 – 2024 key figures at a glance



Save the date!

SWISS BIOTECH DAY 2026

May 4-5, 2026 • Congress Center Basel

